Post-SSRI Sexual Dysfunction: Exploring Contributory Factors and Case Characterization

Emerging evidence suggests that sexual dysfunction linked to selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) can persist long after drug discontinuation in some patients, leading to what is now known as Post-SSRI Sexual Dysfunction (PSSD). In an effort to better understand this condition, a recent study sheds light on the clinical characteristics of PSSD cases and examines potential contributory factors.

The Study: Identifying and Understanding PSSD Cases

Published in the Journal of Clinical Psychopharmacology, the study by Joseph Ben-Sheetrit and colleagues surveyed 532 individuals who experienced sexual dysfunction after taking SSRIs/SNRIs. The goal was to identify patterns, assess symptom severity, and explore the relationship between drug exposure and sexual dysfunction.

Key Findings: Who Is Affected?

Out of 532 participants, 183 were identified as possible PSSD cases, with 23 being classified as high-probability cases. These high-probability cases were marked by the following characteristics:

• Normal sexual function before SSRI/SNRI treatment
• Sexual dysfunction that persisted for at least one month after discontinuation
• No confounding medical conditions, medication use, or drug use
• Normal levels of anxiety and depression, ruling out psychological causes

Genital Anesthesia and Pleasureless Orgasm: Key Predictors

The study found that genital anesthesia and pleasureless orgasms were independent predictors of depression and overall PSSD case probability. Interestingly, while genital anesthesia was linked to current sexual dysfunction, it did not correlate with depression or anxiety, highlighting its unique role in PSSD symptoms.

The Need for Further Research

While this study provides important insights, the authors acknowledge its limitations, including selection biases and the retrospective design. Nonetheless, these findings support the reality of PSSD and suggest that it cannot be fully explained by nonpharmacological factors such as depression or anxiety.

What’s Next?

This study adds to the growing body of evidence confirming the existence of PSSD. However, more research is needed to understand its mechanisms, and the true extent of its impact. As awareness increases, it is crucial that clinicians take this condition seriously and explore potential treatments.

Read the full study here.